You are here
ARONORA INC
UEI: K57JWU3XKX95
# of Employees: 8
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Award Charts
Award Listing
-
Contact Pathway Inhibitor to Prevent Vascular Access Failure
Amount: $998,549.00Project Summary End-stage renal disease (ESRD) patients must maintain chronic vascular access to perform life-saving hemodialysis (HD); however, the HD access portal is extremely vulnerable to infecti ...
SBIRPhase I2023Department of Health and Human Services National Institutes of Health -
Thrombopoietin Targeting in Myeloproliferative Neoplasms
Amount: $700,302.00Project Summary/Abstract Treatment of patients with myeloproliferative neoplasms (MPNs) is limited to palliative and cytoreductive agents that mitigate proliferative blood counts and their effects. Sm ...
SBIRPhase II2023Department of Health and Human Services National Institutes of Health -
Thrombopoietin Targeting in Myeloproliferative Neoplasms
Amount: $301,788.00Project Summary/Abstract Treatment of patients with myeloproliferative neoplasms (MPNs) is limited to palliative and cytoreductive agents that mitigate proliferative blood counts and their effects. Sm ...
SBIRPhase I2022Department of Health and Human Services National Institutes of Health -
Antithrombotic Protein C Activator for Hemodialysis
Amount: $2,997,175.00Project Summary Although potent antithrombotic drugs are available, all inadvertently target vital hemostatic mechanisms, resulting in dose-limiting hemorrhagic toxicity that restricts their use. Due ...
SBIRPhase II2021Department of Health and Human Services National Institutes of Health -
Antithrombotic Protein C Activator for Hemodialysis
Amount: $1,493,466.00Project Summary Although potent antithrombotic drugs are available, all inadvertently target vital hemostatic mechanisms, resulting in dose-limiting hemorrhagic toxicity that restricts their use. Due ...
SBIRPhase II2020Department of Health and Human Services National Institutes of Health -
Factor XII Inhibitor for Surface Initiated Thrombosis
Amount: $2,935,376.00Project Summary Certain life-saving interventions such as cardiopulmonary bypass (CPB), extracorporeal membrane oxygenation (ECMO), hemodialysis, or ventricular assist device (VAD) pumps require the u ...
SBIRPhase II2020Department of Health and Human Services National Institutes of Health -
E-WE thrombin for prevention of post-traumatic osteoarthritis
Amount: $224,997.00Project Summary/Abstract Joint trauma is a significant risk factor for development of osteoarthritis, a leading cause of disability worldwide. Current treatments following traumatic joint injuries inc ...
SBIRPhase I2020Department of Health and Human Services National Institutes of Health -
Antithrombotic Protein C Activator for Hemodialysis
Amount: $994,097.00Project Summary Although potent antithrombotic drugs are availableall inadvertently target vital hemostatic mechanismsresulting in dose limiting hemorrhagic toxicity that restricts their useDue to a l ...
SBIRPhase I2019Department of Health and Human Services National Institutes of Health -
Factor XI inhibitor for thrombosis
Amount: $1,999,050.00Project Summary Although potent antithrombotic agents are availableall of these drugs inadvertently target vital hemostatic molecular mechanismsresulting in dose limiting hemorrhagic toxicity that res ...
SBIRPhase II2018Department of Health and Human Services National Institutes of Health -
Therapeutic Protein C Activator for Myocardial Ischemia
Amount: $2,996,120.00PROJECT SUMMARY Heart attackor acute myocardial infarctionAMIis a leading cause of death in the United Stateswith overvictims every yearThe most prevalent cause of AMI is progressive thrombotic corona ...
SBIRPhase II2017Department of Health and Human Services National Institutes of Health